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Objective: To describe a patient with treatment-refractory pyoderma gangrenosum and
the outcome of a novel therapeutic approach. Methods: Case report and review of the
literature. Results: A patient with inflammatory bowel disease developed severe pyo-
derma gangrenosum while receiving treatment with the chimeric anti-TNF-α antibody
infliximab.Despitesubsequenttrialsofnumerousimmunosuppressiveandimmunomod-
ulatory medications, the dermatologic disease progressed. The patient’s ulcers finally
resolvedwhentreatmentwithadalimumab,afullyhumanizedmonoclonalantibodyspe-
cificforTNF-α,wasinitiated.Conclusions:WereportanovelapplicationoftheTNF-α
inhibitor, adalimumab, in the treatment of pyoderma gangrenosum.
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis associated in 70% of cases
with underlying systemic disease such as inflammatory bowel disease (IBD), rheumatoid
arthritis (RA), monoclonal gammopathy, or malignancy.1,2 Treatment of the underlying
diseaseprocesspromotesPGresolutioninmanycases.Corticosteroidsareconsideredfirst-
line therapy for PG.3 Other immunosuppressive and immunomodulatory agents, including
cyclosporine, thalidomide, tacrolimus, mycophenolate mofetil, and azathioprine, are used
as well. Despite multiple therapeutic options, many cases of PG are refractory to treatment.
Pharmacologic inhibition of the pro-inflammatory cytokine TNF-α has demonstrated
efficacy for a wide range of inflammatory conditions, including IBD, RA, and psoriasis.
There are three TNF-α inhibitors commercially available: etanercept (Enbrel, Immunex
Corporation, Thousand Oaks, CA), a fusion protein dimer of the human TNF-α receptor;
infliximab (Remicade, Centocor Incorporated, Horsham, PA), a chimeric mouse-human
monoclonal antibody to TNF-α; and adalimumab (Humira, Abbott Laboratories, Abbott
Park, IL), a fully human monoclonal antibody to TNF-α. There have been multiple recent
reports of PG successfully treated with infliximab4–12 and etanercept,13–15 including one
randomized controlled trial of infliximab.4 There is also one case report of adalimumab
for a patient with idiopathic PG who had previously suffered an anaphylactoid reaction to
infliximab and failed etanercept therapy.16
Here we present the case of a patient with IBD who developed PG despite receiving
treatment with infliximab. This patient subsequently failed numerous trials of various other
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immunosuppressive and immunomodulatory regimens. We describe our experiences with
the use of adalimumab in this patient.
REPORT OF A CASE
A 38-year-old white woman with a 2-year history of IBD developed a rapidly enlarging,
painful ulcer on her anterior left thigh. For the preceding 6 months, the patient had been on
azathioprine 100 mg daily and infliximab 5 mg/kg infusions once every 8 weeks for active
lymphocytic ileitis. Physical examination revealed a solitary, deep ulcer on her anterior
thigh that was 2.3 cm in diameter, with a characteristic violaceous undermined border and
a painful zone of induration extending 1 cm beyond the ulcer rim. Tissue cultures from
a biopsy of the ulcer edge were negative for bacteria, mycobacteria, and fungi. The skin
biopsyshowednecrosis,amixedinflammatoryinfiltrate,andasmall-vesselleukocytoclastic
vasculitis consistent with PG. Special stains for organisms were negative.
The patient’s PG was resistant to multiple treatment regimens. In addition to the im-
munosuppressive regimen for her IBD (azathioprine and infliximab), local treatments were
initiated, including triamcinolone injections (5 mg/mL) to the ulcer site, topical tacrolimus
0.1% ointment twice daily, and conservative wound care including oral antibiotics. Ini-
tially, the decision was made not to administer systemic corticosteroids as the patient had
previously developed pseudotumor cerebri with ocular manifestations and headache while
receiving prednisone for her IBD. The PG continued to progress over the next month, so
the frequency of infliximab 5 mg/kg infusions was increased to monthly administration.
Monthly high-dose intravenous immunoglobulin (IVIG, 2 g/kg administered in divided
doses over 3 days) was also initiated. When the ulcer depth progressed to the level of the
deep fascia (Fig 1), requiring significant narcotic analgesia for pain control, cyclosporine
3 mg/kg daily was added as well.
Figure 1. LimbMRI.STIRaxialMRIoftheleftlower
extremity demonstrating superficial T2 bright signal
compatible with inflammation involving the subcuta-
neous tissue down to the level of the deep fascia.
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Figure 2. Pyoderma gangrenosum. Large purulent ul-
cer with violaceous undermined borders.
The regimen of cyclosporine, infliximab, azathioprine, and monthly IVIG initially
resulted in improvement of the PG and some re-epithelialization; however, the immuno-
suppression had to be temporarily withdrawn after the patient was hospitalized for aseptic
meningitis. After discharge, the IVIG was restarted, but was then stopped after 2 episodes
of intractable nausea following IVIG infusions. Despite reinitiating cyclosporine and in-
fliximab, the ulceration and surrounding inflammation progressed, eventually involving
an area 8 cm in diameter on her left thigh (Fig 2). A trial of sulfasalazine 2000 mg
(or 2 grams) per day was ineffective as well. Given that her PG was not responding to
multiple immunosuppressive medications, prednisone 20 mg daily was initiated in consul-
tationwithophthalmology.Higherdosesofprednisonewereattempted,butthepatientagain
developed symptoms of pseudotumor cerebri. Because of the patient’s persistent headaches
and visual changes, the prednisone was tapered.
While on infliximab, cyclosporine, and azathioprine, the patient required hospitaliza-
tion for a flare of her IBD and intractable pain from her PG. Adalimumab was then initiated
at 80 mg subcutaneous (SQ) injections every other week in combination with cyclosporine,
prednisone, and sulfasalazine. The ulcer and gastrointestinal disease responded rapidly
(Fig 3), and the patient was discharged on cyclosporine, prednisone, and adalimumab. Over
the next 3 months, cyclosporine and prednisone were tapered and eventually discontinued
asthePGcontinuedtoimprove.ThepatienthasexperiencednorecurrenceofherPGduring
4 months on adalimumab monotherapy (80 mg SQ every other week), though there have
been interval flares of her bowel disease.
DISCUSSION
Pyodermagangrenosumisatypeofpainfulcutaneousulcerassociatedwithunderlyingsys-
temicdiseaseinthemajorityofcases.Thoughthepathophysiologyispoorlyunderstood,PG
isthoughttoberelatedtoimmunedysregulation,includingdefectsinneutrophilchemotaxis,
neutrophil hyperreactivity and overexpression of cytokines such as interleukin-8.17,18Many
of these effects may be mediated by the proinflammatory cytokine TNF-α.
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Figure 3. Healed wound. Residual scarring at area of
pyoderma gangrenosum resolution.
TNF-α has been shown to enhance neutrophil activation, upregulate the expres-
sion of adhesion molecules, and induce the release of chemokines and cytokines from
fibroblasts.13,19 The TNF-α inhibitors infliximab, etanercept, and adalimumab reduce in-
flammationbybindingandinactivatingfreeTNF-α.20 Infliximabandadalimumabhavethe
additional ability to bind surface-bound TNF-α, with subsequent complement fixation and
cell lysis, potentially suppressing T cells and other cells expressing surface TNF.21
Here we describe a patient who developed severe PG despite receiving treatment with
infliximab and azathioprine, whose skin disease proved refractory to multiple subsequent
trials of other immunomodulatory agents as well. Ultimately, this patient’s PG responded
rapidly and dramatically to adalimumab therapy. This case is intriguing because of the
patient’s disparate responses to the 2 anti-TNF-α agents.
We at first suspected that infliximab failed to suppress PG in our patient because of its
immunogenicity as a mouse-human chimeric protein and the resultant formation of human
antichimeric antibodies (HACAs), as infliximab had been administered for 6 months when
the lower-extremity ulceration first appeared. In studies, 10%–61% of patients receiving
infliximab therapy develop HACAs, which have been associated with lower serum inflix-
imab concentrations, decreased duration of treatment response, and decreased infliximab
efficacy.22–25 Incontrast,thefullyhumanagentadalimumabhasthetheoreticaladvantageof
causinglessantidrugantibodyformation,anotionsupportedbyexperimentalassaysdemon-
strating that only 6%–12% of patients develop anti-adalimumab antibodies.26,27 However,
serum assays performed 7 months after infliximab discontinuation in this patient revealed
no detectable HACAs. It is possible that HACAs once present had since disappeared, but
is perhaps more likely that another, as yet uncharacterized, difference between infliximab
and adalimumab contributed to their divergent effects in our patient.
Studies suggest that of the TNF-α inhibitors, infliximab may be most prone to loss of
efficacy over time. Finckh et al28 found that in patients with RA, the problem of gradual
drugfailureisgreaterforinfliximabthanforetanerceptoradalimumab,althoughthisstudy
did not assess levels of antidrug antibodies. Cases of RA and Crohn’s disease that become
refractory to infliximab over time often respond well to adalimumab.26,29–32 In fact, the
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level of therapeutic efficacy achieved with adalimumab in infliximab-resistant patients is
comparable to the improvement achieved when adalimumab is used in TNF-α-inhibitor–
na¨ ıve patients.29,31 Thus, adalimumab may be a valuable treatment for PG patients who fail
to respond to infliximab and other conventional immunosuppressive regimens.
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